Maxim Group analyst Caroline Palomeque downgrades Agile Therapeutics (NASDAQ:AGRX) from Buy to Hold.
Stephens & Co. Reiterates Overweight on Chuy’s Holdings, Maintains $33 Price Target
Stephens & Co. analyst Joshua Long reiterates Chuy's Holdings (NASDAQ:CHUY) with a Overweight and maintains $33 price target.